Cargando…
The prognostic significance of histologic variant on survival outcomes in patients with metastatic urothelial carcinoma receiving immune checkpoint inhibitor therapy
BACKGROUND: While the treatment guidelines have been established for pure urothelial carcinoma (pUC), patients with variant type urothelial carcinoma (vUC) face limited effective treatment options. The effectiveness of immune checkpoint inhibitors (ICI) in patients with vUC remains uncertain and nec...
Autores principales: | Tsai, Tsung-Han, Su, Po-Jung, Huang, Shih-Yu, Kuo, Ming-Chun, Lin, Chang-Ting, Wu, Chia-Che, Luo, Hao-Lun, Chen, Chien-Hsu, Chou, Chih-Chi, Liu, Ting-Ting, Huang, Chun-Chieh, Tsai, Kai-Lung, Su, Yu-Li |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10504763/ https://www.ncbi.nlm.nih.gov/pubmed/37715113 http://dx.doi.org/10.1186/s12885-023-11398-w |
Ejemplares similares
-
First-line Immune Checkpoint Inhibitor Versus Immune Checkpoint Inhibitor With Chemotherapy for Cisplatin-ineligible Metastatic Urothelial Carcinoma: Evidence From a Real-world, Multicenter Analysis
por: Lin, Chang-Ting, et al.
Publicado: (2022) -
Safety and Efficacy of Immune Checkpoint Inhibitors for Patients With Metastatic Urothelial Carcinoma and End-Stage Renal Disease: Experiences From Real-World Practice
por: Kuo, Ming-Chun, et al.
Publicado: (2020) -
Inhibiting WEE1 Augments the Antitumor Efficacy of Cisplatin in Urothelial Carcinoma by Enhancing the DNA Damage Process
por: Su, Yu-Li, et al.
Publicado: (2023) -
Methylation of SPARCL1 Is Associated with Oncologic Outcome of Advanced Upper Urinary Tract Urothelial Carcinoma
por: Luo, Hao-Lun, et al.
Publicado: (2019) -
Biomaterial Material Applications in Postoperative Surgical Fields of Uvulopalatopharyngoplasty: A Comparative Study
por: Yu, Tsung-Che, et al.
Publicado: (2023)